Syndicate content

Capricor Therapeutics to Present on October 7 at Partnering Forum of Stem Cell Meeting; Company Developing Novel Therapeutics for Post-MI, Heart Failure, and DMD Cardiomyopathy; CDC-Derived Exosomes Also Being Investigated for Such Purposes

Capricor Therapeutics, Inc. (NASDAQ:CAPR) a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics announced on September 30, 2015 that Linda Marbán (photo), Ph.D., Capricor’s President, CEO, and Director, will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California (http://stemcellmeetingonthemesa.com). Dr. Marban’s presentation is scheduled for Wednesday, October 7, beginning at 11:45 am Pacific Daylight Time. A live video webcast will be available at http://stemcellmeetingonthemesa.com/webcast/ with a replay of the webcast to be published on http://capricor.com/news/events/. Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures. Capricor’s lead programs target post myocardial infarction (heart attack), heart failure, and Duchenne muscular dystrophy. The company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure, and Duchenne muscular dystrophy-associated cardiomyopathy. CAP-1002 is unique in cardiac cell therapy in that it is the only allogeneic, intracoronary-delivered, cardiosphere-derived cell (CDC) treatment under development. Cenderitide is in development for the outpatient treatment of heart failure, as well as, potentially, other indications. In addition, the Capricor is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For significant additional information on Capricor and its current and planned products please visit www.capricor.com.

[Press release] [Stem Cell Meeting web site] [CAP-1002 product] [Cenderitide product] [Capricor CDC-derived exosomes] [Capricor management team]